Fundz
Free weekly newsletter

Get the free weekly funding digest

The new funding rounds, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New funding rounds, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Industry Trends

See who's moving and how much in your market

No credit card required Weekly funding digest

Sofinnova Partners Announces New Investment In Nephris, An Innovative Biotech Targeting Chronic Kidney Diseases

PRIVATEApr 20, 2022•about 4 years ago
Milan

Description

MILAN, ITALY / April 20, 2022 / Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today a €3 million seed investment in an innovative pre-clinical stage biotech company called Nephris. The Milan-based company is developing novel therapies for diabetic kidney disease, which is a common and serious complication for people with Type 1 or Type 2 diabetes. The investment was made through the Sofinnova Telethon Fund, the venture capital firm's early-stage strategy dedicated to investments in rare and genetic diseases, and the largest fund entirely dedicated to biotechnology in Italy.

Company Information

Company

Nephris

Location

Milan, Lombardy, Italy

About

Nephris is a biotech company developing first-in-class therapies for chronic kidney diseases. Based in Milan, Italy, the company was founded by Paolo Fiorina, full professor of Endocrinology at the University of Milan and world-renowned authority in the domain, and Dr. Francesca D'Addio. The company was established through a €3 million seed financing from Sofinnova Telethon Fund, Sofinnova Partners' early-stage strategy. For more information, please visit: www.nephris.com

Predictive Intelligence
Strategic

ML-powered predictions for Nephris's next move

Learn about Strategic plan

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Nephris? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan